Co-Authors
This is a "connection" page, showing publications co-authored by Fabrizio Cantini and Delia Goletti.
Connection Strength
6.917
-
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled. N Engl J Med. 2021 03 04; 384(9):867-869.
Score: 0.933
-
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect. 2020 10; 81(4):647-679.
Score: 0.889
-
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect. 2020 08; 81(2):318-356.
Score: 0.878
-
Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf. 2019 05; 18(5):415-425.
Score: 0.822
-
Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Rev Anti Infect Ther. 2018 06; 16(6):501-512.
Score: 0.772
-
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. Mediators Inflamm. 2017; 2017:8909834.
Score: 0.719
-
Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Semin Arthritis Rheum. 2017 10; 47(2):183-192.
Score: 0.709
-
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect. 2021 04; 82(4):58-66.
Score: 0.233
-
Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. Drugs. 2020 Dec; 80(18):1929-1946.
Score: 0.229
-
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):286.e7-286.e13.
Score: 0.227
-
Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. J Infect. 2019 07; 79(1):15-23.
Score: 0.204
-
Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. Ther Clin Risk Manag. 2018; 14:2097-2111.
Score: 0.198
-
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci Adv. 2021 01; 7(1).
Score: 0.058
-
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-a agents). Clin Microbiol Infect. 2018 Jun; 24 Suppl 2:S10-S20.
Score: 0.047